News

Deal Announcements

Cognition Therapeutics Nets Venture Capital Debt

Thursday, April 3, 2014 5:55:00 AM PDT | VentureDeal
   Pittsburgh, Pennsylvania  --  Biotechnology company Cognition Therapeutics has secured nearly $6 million in new venture capital debt investment, according to an SEC regulatory filing.

Cognition is focused on developing small molecule therapeutics targeting the toxic proteins associated with Alzheimer's disease.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Cognition is still seeking $7.7 million in additional debt financing, according to the filing.

Minimum investment size per the filing is $3,000.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1